BR112018010292A2 - tratamento de tumores nervosos centrais - Google Patents

tratamento de tumores nervosos centrais

Info

Publication number
BR112018010292A2
BR112018010292A2 BR112018010292A BR112018010292A BR112018010292A2 BR 112018010292 A2 BR112018010292 A2 BR 112018010292A2 BR 112018010292 A BR112018010292 A BR 112018010292A BR 112018010292 A BR112018010292 A BR 112018010292A BR 112018010292 A2 BR112018010292 A2 BR 112018010292A2
Authority
BR
Brazil
Prior art keywords
treatment
central nervous
present
nervous tumors
tumors
Prior art date
Application number
BR112018010292A
Other languages
English (en)
Inventor
Amighi Karim
Van Woensel Matthias
Wauthoz Nathalie
Rosiere Rémi
De Vleeschouwer Steven
Original Assignee
Univ Leuven Kath
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Univ Bruxelles filed Critical Univ Leuven Kath
Publication of BR112018010292A2 publication Critical patent/BR112018010292A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se geralmente a uma nova formulação contendo nanopartículas que encapsulam sirna para o uso de tecnologia de rnai para silenciamento de gene de galectina-1 envolvida na progressão do tumor. mais em particular, a presente invenção se relaciona ao uso de moléculas de rnai para tratamento de central nervous cancer, mais em particular, para tratamento de glioblastoma multiforme (gbm).
BR112018010292A 2015-11-23 2016-11-23 tratamento de tumores nervosos centrais BR112018010292A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520600.6A GB201520600D0 (en) 2015-11-23 2015-11-23 Treatment of central nervous tumours
PCT/EP2016/078547 WO2017089392A1 (en) 2015-11-23 2016-11-23 Treatment of central nervous tumours

Publications (1)

Publication Number Publication Date
BR112018010292A2 true BR112018010292A2 (pt) 2018-11-27

Family

ID=55133198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010292A BR112018010292A2 (pt) 2015-11-23 2016-11-23 tratamento de tumores nervosos centrais

Country Status (10)

Country Link
US (1) US11007154B2 (pt)
EP (1) EP3380087B1 (pt)
JP (1) JP7076103B2 (pt)
CN (1) CN108472265A (pt)
AU (1) AU2016358718B2 (pt)
BR (1) BR112018010292A2 (pt)
CA (1) CA3005992C (pt)
EA (1) EA038254B1 (pt)
GB (1) GB201520600D0 (pt)
WO (1) WO2017089392A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110396524B (zh) * 2019-05-31 2023-05-02 海南大学 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途
CN112716971B (zh) * 2021-01-19 2022-01-25 苏州大学 lncRNA XR_595534.2在制备治疗或预防慢性疼痛的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228274A (zh) * 2005-04-12 2008-07-23 布鲁塞尔大学 靶向半乳凝素-1的基于RNAi的方法用于治疗癌症的用途
CA2729923A1 (en) 2007-07-06 2009-01-15 Aarhus Universitet Dehydrated chitosan nanoparticles
US20130337067A1 (en) 2012-06-15 2013-12-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system

Also Published As

Publication number Publication date
EA038254B1 (ru) 2021-07-30
CA3005992A1 (en) 2017-06-01
JP2018534339A (ja) 2018-11-22
AU2016358718B2 (en) 2022-08-18
CN108472265A (zh) 2018-08-31
US20180344658A1 (en) 2018-12-06
EP3380087A1 (en) 2018-10-03
WO2017089392A1 (en) 2017-06-01
CA3005992C (en) 2024-01-02
EP3380087B1 (en) 2022-06-08
US11007154B2 (en) 2021-05-18
GB201520600D0 (en) 2016-01-06
JP7076103B2 (ja) 2022-05-27
AU2016358718A1 (en) 2018-06-07
EA201891026A1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
CL2020001513A1 (es) Agente terapéutico que induce citotoxicidad. (divisional solicitud 201700704)
NZ741324A (en) Anti-cd47 antibodies and methods of use
EA201991369A1 (ru) Модифицированные направляющие рнк
BR112019017743A2 (pt) rna terapêutico
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
CY1121185T1 (el) Αδενοϊος που εκφραζει fas-χιμαιρα και χρηση αυτης σε μεθοδους θεραπειας καρκινου
BR112015023001A2 (pt) composição de salto de exon para tratamento de distrofia muscular
BR112015004747A2 (pt) moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas
CY1124006T1 (el) Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112017022281A2 (pt) métodos para tratar câncer
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
BR112018010292A2 (pt) tratamento de tumores nervosos centrais
IN2014CN03921A (pt)
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
WO2015020993A3 (en) RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]